Drugs / Dihydroartemisinin-piperaquine
Dihydroartemisinin-piperaquine
Trials 33
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 01 trial | ||||||
| Phase 0 | NCT07021430 | Jul 2026 → Jul 2028 expected | malaria | University of North Carolina, Chapel Hill | Not yet recruiting | No outcome recorded |
| Phase 12 trials | ||||||
| Phase 1 | NCT02612545 | Nov 2015 → Oct 2018 | Plasmodium falciparum malaria | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
| Phase 1 | NCT01525511 | Jun → Sep 2012 | — | University of Oxford | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT01165372 | Aug 2010 → May 2011 | malaria | Oxford University Clinical Research Unit, Vietnam | Completed | No outcome recorded |
| Phase 39 trials · 2 met primary · 3 missed | ||||||
| Phase 3 | NCT05426434 | Aug 2022 → Mar 2025 overdue | malaria, pregnancy disorder | Menzies School of Health Research | Active not recruiting | No outcome recorded |
| Phase 3 | NCT03640403 | Mar 2019 → Dec 2020 | Plasmodium falciparum malaria, anemia | National Institute for Medical Research, Tanzania | Completed | Mixed |
| Phase 3 | NCT03208179 | Mar 2018 → Mar 2020 | malaria, pregnancy disorder | Liverpool School of Tropical Medicine | Completed | Missed primary |
| Phase 3 | NCT03009526 | Jan 2017 → Oct 2018 | Plasmodium falciparum malaria | Kamuzu University of Health Sciences | Completed | No outcome recorded |
| Phase 3 | NCT02315690 | Sep 2015 → Jul 2017 | malaria | University of California, San Francisco | Completed | Missed primary |
| Phase 3 | NCT02605720 | Sep 2015 → Jan 2016 | malaria | Lihir Medical Centre | Completed | No outcome recorded |
| Phase 3 | NCT02987270 | Apr 2013 → Aug 2015 | Plasmodium falciparum malaria | Simon Kariuki | Completed | Missed primary |
| Phase 3 | NCT00852423 | Jun 2010 → Oct 2013 | Plasmodium falciparum malaria | Institute of Tropical Medicine, Belgium | Completed | Met primary |
| Phase 3 | NCT00527800 | Aug 2007 → Mar 2013 | HIV infectious disease, malaria | University of California, San Francisco | Completed | Met primary |
| Phase 415 trials · 2 met primary · 1 missed | ||||||
| Phase 4 | NCT07322068 | Sep 2026 → Jun 2033 expected | Plasmodium falciparum malaria | Stanford University | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT06083688 | Oct 2024 → Jul 2025 overdue | Plasmodium falciparum malaria, anemia | Liverpool School of Tropical Medicine | Active not recruiting | No outcome recorded |
| Phase 4 | NCT05980156 | Feb → Jul 2023 | Plasmodium falciparum malaria, anemia | University of Maryland, Baltimore | Completed | No outcome recorded |
| Phase 4 | NCT05244954 | Feb → Aug 2022 | Plasmodium falciparum malaria, anemia | University of Maryland, Baltimore | Completed | No outcome recorded |
| Phase 4 | NCT04487145 | Nov 2020 → Apr 2022 | HIV infectious disease | University of California, San Francisco | Completed | No outcome recorded |
| Phase 4 | NCT04245033 | Jul 2020 → May 2021 | malaria | National Institute for Medical Research, Tanzania | Completed | No outcome recorded |
| Phase 4 | NCT04160026 | Nov 2019 → Jul 2020 | Plasmodium falciparum malaria | Liverpool School of Tropical Medicine | Completed | Met primary |
| Phase 4 | NCT03431714 | Jul → Dec 2017 | Plasmodium falciparum malaria | National Institute for Medical Research, Tanzania | Completed | No outcome recorded |
| Phase 4 | NCT04897919 | Aug 2015 → Oct 2017 | malaria | Bandim Health Project | Completed | No outcome recorded |
| Phase 4 | NCT02590627 | May 2014 → Dec 2015 | malaria | National Institute for Medical Research, Tanzania | Completed | No outcome recorded |
| Phase 4 | NCT02009215 | Feb 2014 → Apr 2015 | malaria | London School of Hygiene and Tropical Medicine | Completed | Missed primary |
| Phase 4 | NCT01878357 | Jun → Nov 2013 | malaria | Indonesia University | Completed | No outcome recorded |
| Phase 4 | NCT01755559 | Jun 2013 → Nov 2014 | malaria | Epicentre | Completed | Met primary |
| Phase 4 | NCT01775592 | Sep 2012 → Jan 2013 | Plasmodium falciparum malaria | National Institute of Malariology, Parasitology and Entomology, Vietnam | Completed | No outcome recorded |
| Phase 4 | NCT01075945 | Feb → Apr 2010 | malaria | University of Khartoum | Unknown | No outcome recorded |
| Phase not applicable5 trials · 2 missed | ||||||
| — | NCT06870344 | Mar 2025 → Oct 2026 expected | Plasmodium falciparum malaria | University of North Carolina, Chapel Hill | Active not recruiting | No outcome recorded |
| — | NCT02878200 | Nov 2016 → Dec 2018 | malaria | London School of Hygiene and Tropical Medicine | Completed | Missed primary |
| — | NCT02721186 | Apr → Dec 2016 | malaria | Ulrika Morris | Completed | Missed primary |
| — | NCT02914145 | Nov 2015 → Dec 2017 | malaria | Manhiça Health Research Centre | Completed | No outcome recorded |
| — | NCT01280162 | Sep 2010 → Feb 2011 | malaria | Armed Forces Research Institute of Medical Sciences, Thailand | Completed | No outcome recorded |
| Comparator or background therapy12 trials | ||||||
| Phase 1 | NCT01552330 Comparator | May → Oct 2012 | — | University of Oxford | Completed | No outcome recorded |
| Phase 2 | NCT02511353 Background | Jul 2015 → Jul 2016 | malaria | Liverpool School of Tropical Medicine | Completed | Met primary |
| Phase 3 | NCT04844905 Background | May 2021 → Mar 2023 | Plasmodium falciparum malaria, filariasis, hookworm infectious disease, scabies +1 | London School of Hygiene and Tropical Medicine | Unknown | Missed primary |
| Phase 3 | NCT04336189 Comparator | Dec 2020 → Jul 2024 | malaria | Grant Dorsey, M.D, Ph.D. | Completed | No outcome recorded |
| Phase 3 | NCT02802501 Background | Apr 2018 → Aug 2019 | Plasmodium vivax malaria | GlaxoSmithKline | Completed | Met primary |
| Phase 3 | NCT02721420 Background | Mar 2016 → Mar 2019 | anemia, malaria | Kamuzu University of Health Sciences | Unknown | No outcome recorded |
| Phase 3 | NCT02259426 Background | Oct 2014 → Sep 2015 | Plasmodium falciparum malaria | London School of Hygiene and Tropical Medicine | Completed | No outcome recorded |
| Phase 3 | NCT02163447 Comparator | Jun 2014 → May 2018 | malaria | Grant Dorsey, M.D, Ph.D. | Completed | No outcome recorded |
| Phase 4 | NCT04767217 Comparator | Jun 2021 → Dec 2023 | malaria | Jhpiego | Completed | No outcome recorded |
| Phase 4 | NCT02192944 Comparator | Jul 2014 → Sep 2015 | — | University of Oxford | Completed | No outcome recorded |
| — | NCT05874869 Comparator | Jul 2020 → Jun 2021 | malaria | Richard Mwaiswelo | Completed | No outcome recorded |
| — | NCT05060198 Comparator | Jun 2016 → Mar 2017 | Plasmodium falciparum malaria | Kenya Medical Research Institute | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 2
| Date | Issuer | Release |
|---|---|---|
| 2020-12-04 | Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd. | Results Fosun Pharma Invites Top-Experts to Discuss New Trends in Maternal and Childhood Malaria Chemoprevention for 9th eCME fosunpharma.com ↗
Trials of ITPp with Dihydroartemisinin-Piperaquine (DHA-PPQ) vs. SP show significantly less clinical malaria, less malaria during pregnancy and less moderate anaemia. |
| 2019-11-21 | Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd. | Regulatory Fosun Pharma Achieves Another Breakthrough for its Artemisinin Preparation First Dihydroartemisinin-piperaquine Phosphate Product for Use in Children Receives WHO Pre-certification fosunpharma.com ↗
On 21 November 2019, Shanghai Fosun Pharmaceutical (Group) Co., Ltd (“Fosun Pharma”or“Group”; Stock Code: 600196.SH, 02196.HK) announced that 2 strengths of D-ARTEPP Dispersible (dihydroartemisinin-piperaquine phosphate dispersible tablets) and 2 strengths of D-ARTEPP (dihydroartemisinin-piperaquine phosphate tablets) developed by its subsidiary Guilin Pharmaceutical Co., Ltd. (“Guilin Pharma”) have is prequalified by the World Health Organization (WHO prequalification of medicine, “WHO PQ”). |
All press releases naming this drug 2 releases
| Date | Issuer | Release |
|---|---|---|
| 2020-12-04 | Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd. | Fosun Pharma Invites Top-Experts to Discuss New Trends in Maternal and Childhood Malaria Chemoprevention for 9th eCME fosunpharma.com ↗ |
| 2019-11-21 | Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd. | Fosun Pharma Achieves Another Breakthrough for its Artemisinin Preparation First Dihydroartemisinin-piperaquine Phosphate Product for Use in Children Receives WHO Pre-certification fosunpharma.com ↗ |
Evidence & citations 16 cited values
Every value below carries the sentence it was read from. 49 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | dihydroartemisinin piperaquine | “Dihydroartemisinin-piperaquine (DHA-PQP); the fixed-dose combination of Dihydroartemisinin (DHA) and Piperaquine phosphate (PQP) is now one of the recommended drugs by WHO as...” NCT01525511 ↗45“Subject will receive primaquine (PQ) then receive PQ together dihydroartemisinin-piperaquine (DHA-PQP) after 1 week washout period and receive DHA-PQP for the third regimen...” NCT01552330 ↗ “The study assessed the efficacy and safety of artesunate-amodiaquine (ASAQ) and dihydroartemisinin-piperaquine (DP) for the treatment of uncomplicated malaria in Tanzania.” NCT03431714 ↗ “The study assessed the efficacy and safety of artesunate-amodiaquine (ASAQ) and dihydroartemisinin-piperaquine (DP) for the treatment of uncomplicated malaria in Tanzania.” NCT03431714 ↗ “Dihydroartemisinin-piperaquine (DP) is a WHO pre-qualified artemisinin combination therapy widely used for the treatment of uncomplicated malaria.” NCT06870344 ↗ “Delayed parasite clearance after treatment with dihydroartemisinin-piperaquine in Plasmodium falciparum malaria patients in central Vietnam.” PMID 25224002 ↗ Sep 2014 “Monthly IPTp with dihydroartemisinin-piperaquine, a 3-day regimen, is an emerging alternative” PMID 39304238 ↗ Oct 2024 “dihydroartemisinin-piperaquine (DHAp) + single low dose (SLD) primaquine” NCT02721186 ↗ |
| Known as | Artekin | “Dihydroartemisinin-piperaquine combination (Artekin)” NCT02259426 ↗ |
| Known as | Arterakin | “Arterakin (DHA-PPQ)” NCT01775592 ↗ |
| Known as | D-ARTEPP | “dihydroartemisinin-piperaquine (D-ARTEPP, Guilin Pharmaceutical (Shanghai) Co., Ltd., China)” NCT02721186 ↗ |
| Known as | DHA-PPQ | “A WHO standard protocol was used to assess efficacy of the combinations artesunate-amodiaquine (AS-AQ Winthrop®), dihydroartemisinin-piperaquine (DHA-PPQ, Eurartesim®) and...” PMID 29370844 ↗ Jan 20184“Dihydroartemisinin-piperaquine (DHA/PPQ) given monthly for 3 months” NCT02605720 ↗ “dihydroartemisinin-piperaquine (DHA-PPQ)” NCT04767217 ↗ “Dihydroartemisinin-piperaquine (DHA-PPQ)” NCT02612545 ↗ “Arterakin (DHA-PPQ)” NCT01775592 ↗ |
| Known as | DHA-PQ | “DHA-PQ tablets are green film coated intended for oral use and contain 20/160mg or 40/320mg of dihydroartemisinin (DHA) and piperaquine phosphate (PQ) respectively.” NCT00852423 ↗ |
| Known as | DHA-PQP | “Subject will receive primaquine (PQ) then receive PQ together dihydroartemisinin-piperaquine (DHA-PQP) after 1 week washout period and receive DHA-PQP for the third regimen...” NCT01552330 ↗2“dihydroartemisinin-piperaquine (DHA-PQP)after 1 week washout period” NCT01525511 ↗ “Dihydroartemisinin-piperaquine (DHA-PQP)” NCT02802501 ↗ |
| Known as | DHAp | “In the fMDA arm, all individuals in the target area will receive dihydroartemisinin-piperaquine (DHAp) once daily for 3 days with the first dose taken no later than 5 weeks...” NCT02315690 ↗1“two rounds of MDA with dihydroartemisinin-piperaquine (DHAp) + single low dose (SLD) primaquine” NCT02721186 ↗ |
| Known as | DHP | “In Malawi, there is an on-going cluster randomised trial that aims to find the optimum strategy for delivery of dihydroartemesinin-piperaquine (DHP) for PMC in children with...” PMID 30567567 ↗ Dec 20181“The drug that will be given is 3-day dihydroartemisinin-piperaquine (DHP) treatment.” NCT01878357 ↗ |
| Known as | dihydroartemesinin-piperaquine | “In Malawi, there is an on-going cluster randomised trial that aims to find the optimum strategy for delivery of dihydroartemesinin-piperaquine (DHP) for PMC in children with...” PMID 30567567 ↗ Dec 2018 |
| Known as | Dihydroartemisinin (DHA)-Piperaquine | “An Active Malaria Epidemiology Cohort Study With Evaluation of a 2 Day Versus 3 Day Treatment Regimen of Dihydroartemisinin (DHA)-Piperaquine for Patients With Uncomplicated Malaria” NCT01280162 ↗ |
| Known as | Dihydroartemisinin-Piperaquine (DP) | “This is an active observational Cohort Study of malaria epidemiology with a nested two arm, randomized, open label Treatment Study comparing the efficacy, safety, tolerability...” NCT01280162 ↗ |
| Known as | Dihydroartemisnin- piperaquine -Eurartesim | “Dihydroartemisnin- piperaquine -Eurartesim®” NCT04160026 ↗ |
| Known as | Duo-Cotecxin | “DP (Duo-Cotecxin) will be supplied by Holley-Cotec, Beijing, China.” NCT04336189 ↗ |
| Known as | Eurartesim | “A WHO standard protocol was used to assess efficacy of the combinations artesunate-amodiaquine (AS-AQ Winthrop®), dihydroartemisinin-piperaquine (DHA-PPQ, Eurartesim®) and...” PMID 29370844 ↗ Jan 20181“DHA-PQP: * 1 tablet of Eurartesim contains: DHA 40 mg: piperaquine 320 mg” NCT01525511 ↗ |
| Route | Oral | “intended for oral use” NCT00852423 ↗ |